| Cogent Biosciences is a biotechnology company focused on developing therapies for genetically defined diseases. Co.'s approach is to design therapies that treat the underlying cause of disease and improve the lives of patients. Co.'s main program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. Bezuclastinib is a highly selective KIT inhibitor with the potential to provide a new treatment option for these patient populations. In addition, Co.'s research team is developing a portfolio of targeted therapies to help patients fighting serious, genetically driven diseases. We show 15 historical shares outstanding datapoints in our coverage of COGT's shares outstanding history.
Understanding the changing numbers of COGT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like COGT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching COGT by allowing them to research COGT shares outstanding history
as well as any other stock in our coverage universe.